CNK Price Prediction Next Week
Technical Analysis: CNK shows a bearish trend with RSI at 26.50, indicating oversold conditions. The stock is trading below all major moving averages (5-day: $26.18, 10-day: $28.03, 20-day: $29.35). MACD (-1.12) displays a negative momentum with bearish divergence.
Price Levels:
- Support levels: $23.85 (Fibonacci S2), $25.78 (Fibonacci S1)
- Resistance levels: $31.99 (Fibonacci R1), $33.92 (Fibonacci R2)
News Impact:
- Cineworld's potential merger exploration with competitors including CNK could create short-term price volatility
- The stock recently entered oversold territory, suggesting potential for a technical bounce
Price Prediction for Next Week: Based on technical indicators and news sentiment:
- Entry: $25.70 (current price)
- Target price: $24.50-25.00
- Stop loss: $26.50
Recommendation: SELL Rationale:
- Bearish momentum confirmed by negative MACD
- Price trading below all major moving averages
- Despite oversold conditions, merger news uncertainty could create downward pressure
- Fibonacci support levels suggest room for further downside
The stock is likely to test the Fibonacci S1 level at $25.78 before potentially moving towards S2 at $23.85. Traders should monitor volume for confirmation of price movements and maintain strict stop-loss orders.
CNK Similar Chart Price Prediction
The price of CNK is predicted to go up 7.48%, based on the high correlation periods with BIIB. The similarity of these two price pattern on the periods is 97.31%.
CNK
BIIB
Up: 7.48%Similarity: 97.31%
CNK Revenue Forecast
CNK EPS Forecast
CNK FAQs
What is bull’s view on CNK?
What is bear's view on CNK?
What is CNK revenue forecast for next quarter？
CNK Analyst's Forecast
Benjamin Swinburne
Morgan Stanley
Buy
2025-02-20
Price Target
$40 → $35
Upside
+25.94%
Morgan Stanley lowered the firm's price target on Cinemark to $35 from $40 and keeps an Overweight rating on the shares. Continued strong box office recovery has given Cinemark greater confidence in increased investment, lowering near-term free cash flow estimates, but the firm views the recent share weakness as "a compelling buying opportunity" with expectations reset around both adjusted EBITDA margins and capital spending, the analyst tells investors in a post-earnings note.
Mike Hickey
Benchmark
Strong Buy
2025-02-20
Price Target
$40 → $35
Upside
+25.94%
James Goss
Barrington Research
Buy
2025-02-20
Price Target
$40 → $36
Upside
+29.54%
